President Donald Trump's nominee to lead the FDA, Stephen Hahn, stated that he plans to uphold the agency's approval standards for drugs and devices, and supports the use of patient-focused endpoints to expedite drug and medical device clinical trials. "I believe strongly in the importance of science, data and the law that have guided and should continue to guide the decision making at the FDA," says Hahn on drugs and medtech oversight.
Hahn supports use of patient-focused endpoints in drugs, device trials
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.